Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.78
-0.04 (-0.69%)
Feb 21, 2025, 4:00 PM EST - Market closed
Abeona Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Abeona Therapeutics stock have an average target of 17.25, with a low estimate of 15 and a high estimate of 21. The average target predicts an increase of 198.44% from the current stock price of 5.78.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Abeona Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +159.52% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +159.52% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +159.52% | Oct 31, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $18 | Buy | Reiterates | $18 | +211.42% | Oct 29, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $18 | Buy | Reiterates | $18 | +211.42% | Sep 20, 2024 |
Financial Forecast
Revenue This Year
127.50K
from 3.50M
Decreased by -96.36%
Revenue Next Year
20.17M
from 127.50K
Increased by 15,721.96%
EPS This Year
-1.72
from -2.53
EPS Next Year
-1.24
from -1.72
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 525,000 | 30.6M | 111.4M | |||
| Avg | 127,500 | 20.2M | 77.4M | |||
| Low | n/a | 14.4M | 55.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -85.0% | 23,864.7% | 452.3% | |||
| Avg | -96.4% | 15,722.0% | 283.9% | |||
| Low | - | 11,168.2% | 176.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.60 | -1.06 | -0.08 | |||
| Avg | -1.72 | -1.24 | -0.40 | |||
| Low | -1.76 | -1.48 | -0.86 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.